Cargando…

Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study

The optimal therapeutic options, adding locoregional therapy (LRT) to systemic therapy (ST) or not, for patients with oligometastatic breast cancer (OMBC) have not been fully elucidated. Hence, we designed a retrospective observational study which enrolled patients with measurable extracranial OMBC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuyu, Duan, Fangfang, Zhuang, Yue, Song, Chenge, Huang, Jiajia, Xia, Wen, Hong, Ruoxi, Zheng, Qiufan, Wang, Shusen, Shi, Yanxia, Xu, Fei, Yuan, Zhongyu, Bi, Xiwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553526/ https://www.ncbi.nlm.nih.gov/pubmed/36245976 http://dx.doi.org/10.1155/2022/7839041

Ejemplares similares

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
por: Duan, Fangfang, et al.
Publicado: (2022)

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer
por: Zhou, Danyang, et al.
Publicado: (2021)

Locoregional control and survival after lymph node SBRT in oligometastatic disease
por: Loi, Mauro, et al.
Publicado: (2018)

What is the appropriate genetic testing criteria for breast cancer in the Chinese population?—Analysis of genetic and clinical features from a single cancer center database
por: Ni, Mengqian, et al.
Publicado: (2023)

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
por: Lu, Qianyi, et al.
Publicado: (2020)

Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2021)

A Novel Prognostic Model Based on the Serum Iron Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Hua, Xin, et al.
Publicado: (2021)

An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer
por: Yuan, Jing, et al.
Publicado: (2021)

High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study
por: Su, Yanhong, et al.
Publicado: (2021)

Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy
por: Jiang, Kuikui, et al.
Publicado: (2020)

Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?
por: Ghidini, Michele, et al.
Publicado: (2019)

Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer: A Retrospective Cohort Analysis
por: Zheng, Qiufan, et al.
Publicado: (2015)

Radiation therapy for oligometastatic oropharyngeal cancer
por: Martini, Stefania, et al.
Publicado: (2020)

The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
por: An, Xin, et al.
Publicado: (2018)

The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence
por: Zhou, Danyang, et al.
Publicado: (2023)

Locoregional therapy of renal cancer
por: Wah, Tze Min
Publicado: (2014)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma
por: Owen, Mackenzie, et al.
Publicado: (2023)

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2022)

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study
por: Hong, Ruoxi, et al.
Publicado: (2021)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma
por: Roux, Charles, et al.
Publicado: (2022)

Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy
por: Li, Jiaping, et al.
Publicado: (2023)

A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer
por: Hua, Xin, et al.
Publicado: (2022)

Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors
por: Jiang, Kuikui, et al.
Publicado: (2023)

Update on Locoregional Therapies for Cholangiocellular Carcinoma
por: Morawitz, Janna, et al.
Publicado: (2023)

Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival
por: Beal, Eliza W., et al.
Publicado: (2016)

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer
por: Miura, Yuji, et al.
Publicado: (2019)

Multimodal therapy in urachal carcinoma with oligometastatic bone disease
por: García Alvarez, C., et al.
Publicado: (2019)

The changing role of radiation therapy in the management of oligometastatic disease
por: Tharmalingham, H., et al.
Publicado: (2017)

Radiation therapy for oligometastatic bone disease in breast cancer
por: Katayama, Norihisa, et al.
Publicado: (2020)

Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer
por: Luo, Hanjia, et al.
Publicado: (2023)

Preclinical Study of Locoregional Therapy of Hepatocellular Carcinoma by Bioelectric Ablation with Microsecond Pulsed Electric Fields (μsPEFs)
por: Chen, Xinhua, et al.
Publicado: (2015)

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population
por: Wang, Liye, et al.
Publicado: (2021)

Long-term survival in node-positive breast cancer treated by locoregional therapy alone.
por: Joensuu, H., et al.
Publicado: (1998)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma: The Role of Intra-Arterial Therapies
por: Gorji, Leva, et al.
Publicado: (2023)

Survival and prognostic factors in oligometastatic breast cancer
por: van Ommen-Nijhof, Annemiek, et al.
Publicado: (2022)

Complications following locoregional therapy of renal cancer
por: Krokidis, Miltiadis
Publicado: (2014)

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies
por: Bazeed, Alaa Y., et al.
Publicado: (2022)

Salvage locoregional therapies for recurrent hepatocellular carcinoma
por: Criss, Cody R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dkugiji4ghuk0g7kmsj3ld9s45